Global Ovarian Cancer Diagnostics Market Size study & Forecast, by Diagnosis Type (Imaging, Blood Test, Biopsy, Others), by Cancer Type (Epithelial Tumor, Stromal Cell Tumor, Germ Cell Tumor, Others), by End Use (Hospital Laboratories, Cancer Diagnostic C

Global Ovarian Cancer Diagnostics Market Size study & Forecast, by Diagnosis Type (Imaging, Blood Test, Biopsy, Others), by Cancer Type (Epithelial Tumor, Stromal Cell Tumor, Germ Cell Tumor, Others), by End Use (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Others), and Regional Analysis, 2023-2030

Global Ovarian Cancer Diagnostics Market is valued at approximately USD 1.53 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.2% over the forecast period 2023-2030. Ovarian cancer is a type of cancer that starts in the ovaries, which are the female organs responsible for producing eggs. This cancer is most commonly found in women aged 50 to 79 and is becoming more prevalent as the world's elderly population grows. Early detection and treatment are key in managing ovarian cancer, and initiatives by governments and organizations are driving market growth. However, a lack of skilled professionals hinder the market growth.

The increasing number of cases of ovarian cancer across the globe is driving the market. According to a report by the National Cancer Institute in the US, the rate of new cases of ovarian cancer is 10.3 per 100,000 women per year, with a death rate of 6.3 per 100,000 women per year. This shows how lethal this disease be. Governments and organizations are investing in research and development for ovarian cancer diagnosis and treatment which is boosting the market growth. Such as the Ovarian Cancer Research Alliance (OCRA), a non-profit organization. Additionally, healthcare expenditure for cancer treatment is increasing, allowing patients to access advanced diagnostics and treatment for faster recovery. Market players are also launching innovative products, such as Inex Innovate's OvaCis Rapid test for ovarian cancer detection, which boosts the overall market growth. However, due to costlier cancer treatment it poses challenges to market growth. According to the report of the National Cancer Institute, in 2018, costs for cancer care were estimated at USD 201.19 billion, projected to increase to USD 208.9 billion in 2020 due to population growth and aging. This impact market growth until 2030.

The key regions considered for the Global Ovarian Cancer Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022. The region's growth can also be attributed to favorable government initiatives, increased healthcare expenditure, and the presence of key manufacturers. The American Cancer Society estimates that about 19,710 women in the US would be receiving a new diagnosis of ovarian cancer in 2023, with approximately 13,270 women dying from the disease. Ovarian cancer ranks fifth in cancer deaths among women, in U.S. Asia Pacific is expected to grow significantly over the forecast period, owing to factors such as overall economic development, improved healthcare infrastructure, increased disposable income, and greater consumer awareness.


Major market player included in this report are:
Abcam plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
AstraZeneca plc
Siemens Healthcare GmbH
Quest Diagnostics Incorporated.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Abbott. Laboratories Inc.

Recent Developments in the Market:
 In November 2022, Myriad Genetics Inc. announced, it had acquired Gateway Genomics, LLC to strengthen its portfolio of Women’s Health products. This move aims to enhance their Women's Health products portfolio, providing personalized genetic tests that can be accessed during and after a woman's reproductive stage. With SneakPeek, Myriad can now offer genetic insights earlier in pregnancy, providing women with valuable data throughout their lifetime. The company's Prequel non-invasive prenatal screen, Foresight carrier screen, and MyRisk Hereditary Cancer Test with Risk Scores for all ancestries are expected to increase revenue.
 In November 2022, Roche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay became the first IHC-based companion diagnostic to receive FDA approval. It can identify ovarian cancer patients eligible for ELAHERE, providing a new option for treatment.
 In November 2021, the USFDA approved an imaging drug called Cytalux (pafolcianine) that illuminates ovarian cancer tissue when exposed to fluorescent light, making it easier and more precise for surgeons to remove the cancer.

Global Ovarian Cancer Diagnostics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Diagnosis Type, Cancer Type, End Use, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:


By Diagnosis Type:
Imaging
Blood Test
Biopsy
Others

By Cancer Type:
Epithelial Tumor
Germ Cell Tumor
Stromal Cell Tumor
Others

By End Use:
Hospital Laboratories
Cancer Diagnostic Centers
Research Institutes
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Abcam plc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
AstraZeneca plc
Siemens Healthcare GmbH
Quest Diagnostics Incorporated.
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Abbott. Laboratories Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.